The international management consulting company McAlpine Thorpe and Warrier Ltd, which specializes in the field of herbal medicines, has announced proposals for a multiclient study of the market for herbal medicines in the Far East and Southeast Asia, over the period 1992-96.
The countries to be covered by the study are India, Pakistan, Indonesia, the Philippines, Japan, Singapore, Korea, Taiwan, Malaysia and Thailand.
Of the rapid growth which the herbal medicines industry has experienced globally in recent years, nowhere has this been higher than in the Far East and Southeast Asia, says MTW. Yet this potential has been largely ignored by manufacturers, which have generally preferred to explore the opportunities presented by the single European Community market after 1992.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze